타이틀카지노

ASCO 2025: Gut-Associated Checkpoint as a Prognostic Biomarker in Metastatic Renal Cell Carcinoma (mRCC): Results from a Randomized First-Line Clinical Trial

UroToday

2025-06-01 09:08:59

ASCO: Combo Therapy Pre-Surgery Boosts Rare Thyroid Cancer Survival

Mirage News

2025-06-01 07:10:00

ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer

FirstWord Pharma

2025-06-01 05:26:12

ASCO25: ArteraAI's multimodal AI tool redefines risk stratification in prostate cancer

FirstWord Pharma

2025-05-31 11:25:28

ASCO 2025: Exploratory Analyses of Homologous Recombination Repair Alterations by Gene Subgroup and Potential Associations with Efficacy in the HRR-Deficient Population from TALAPRO-2

UroToday

2025-05-31 07:33:38

Mascotas al Parque: el festival pet-friendly que transforma el ocio en bienestar | LAUD

Universidad Distrital Francisco Jose de Caldas

2025-05-31 07:30:10

ASCO 2025: Duration of Response Following Treatment with UGN-102 in Patients with Recurrent, Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer: 18-Month Data from the Phase 3 ENVISION Trial

UroToday

2025-05-31 07:28:23

ASCO 2025: Impact of Germline Versus Somatic BRCA Mutation Status on the Efficacy of Rucaparib Versus Physician’s Choice in the TRITON3 Study of Patients with mCRPC

UroToday

2025-05-31 06:33:19

ASCO 2025: FGFR3 Alteration Status and Outcomes with Immune Checkpoint Inhibitors in Patients with Metastatic Urothelial Carcinoma

UroToday

2025-05-31 06:28:26

ASCO 2025: Additive Clinical Utility of Tissue Biomarkers of Microsatellite Instability Status and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness for Real-World Patients with mCRPC

UroToday

2025-05-31 05:13:13

ASCO 2025: Circulating Tumor DNA in Patients with MIBC Who Received Perioperative Durvalumab in NIAGARA

UroToday

2025-05-31 05:13:13

ASCO 2025: CLONEVO: Preoperative Abemaciclib for Cisplatin Ineligible MIBC with Molecular Response Assessment

UroToday

2025-05-31 00:47:11

ASCO 2025: Five-Year Follow-up Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab for the Treatment of Clear Cell RCC

UroToday

2025-05-31 00:37:16

ASCO25: AI test shown to aid in prostate cancer treatment planning

Yahoo

2025-05-30 20:45:53

ASCO 2025: Alcohol-Fueled Cancer Deaths Are on the Rise in the U.S. | Newswise

Newswise

2025-05-30 05:50:00

Diakonos Oncology to Present Phase I Results of Dubodencel (DOC1021), a Double-Loaded Dendritic Cell Therapy for Glioblastoma, at the ASCO 2025 Annual Meeting

FirstWord Pharma

2025-05-30 05:45:28

Bexion Pharmaceuticals, Inc. Announces Acceptance of Abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire

2025-05-29 05:14:52

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

Medical Xpress

2025-05-29 04:32:14

Avviso pubblico per l'affidamento in concessione della palestra “Don Vinicio Vivaldi” di San Miniato Basso per il tempo extrascolastico

Comune di San Miniato

2025-05-28 20:57:00

KAHR Bio Announces Oral Presentation of Phase 2 Study of DSP107 in Combination with anti-PD-L1 in Colorectal Cancer at 2025 ASCO Annual Meeting

FirstWord Pharma

2025-05-28 06:12:39

2030세대가 가입하면 좋은 세테크 금융상품 총정리